我要吃瓜

Article

Neuroblastoma arginase activity creates an immunosuppressive microenvironment impairing autologous and engineered immunity

Details

Citation

Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L & De Santo C (2015) Neuroblastoma arginase activity creates an immunosuppressive microenvironment impairing autologous and engineered immunity. Cancer Research, 75 (15), pp. 3043-3053. https://doi.org/10.1158/0008-5472.CAN-14-3443

Abstract
Neuroblastoma is the most common extracranial solid tumor of childhood, and survival remains poor for patients with advanced disease. Novel immune therapies are currently in development, but clinical outcomes have not matched preclinical results. Here, we describe key mechanisms in which neuroblastoma inhibits the immune response. We show that murine and human neuroblastoma tumor cells suppress T-cell proliferation through increased arginase activity. Arginase II is the predominant isoform expressed and creates an arginine-deplete local and systemic microenvironment. Neuroblastoma arginase activity results in inhibition of myeloid cell activation and suppression of bone marrow CD34+progenitor proliferation. Finally, we demonstrate that the arginase activity of neuroblastoma impairs NY-ESO-1–specific T-cell receptor and GD2-specific chimeric antigen receptor–engineered T-cell proliferation and cytotoxicity. High arginase II expression correlates with poor survival for patients with neuroblastoma. The results support the hypothesis that neuroblastoma creates an arginase-dependent immunosuppressive microenvironment in both the tumor and blood that leads to impaired immunosurveillance and suboptimal efficacy of immunotherapeutic approaches.

Journal
Cancer Research: Volume 75, Issue 15

StatusPublished
Publication date01/08/2015
Publication date online08/06/2015
Date accepted by journal09/05/2015
URL
PublisherAmerican Association for Cancer Research
ISSN0008-5472
eISSN1538-7445